☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Alagille Syndrome
Mirum Reports Six Years Results of LIvmarli (maralixibat) for the Treatment of Alagille Syndrome
November 16, 2021
Celltrion's Regdanvimab Receives the EC's Approval for the Treatment of COVID-19
November 16, 2021
Mirum's Livmarli (maralixibat) Receives US FDA's Approval as the First Approved Therapy for Cholestatic Pruritus in Patients with...
September 29, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.